Results 321 to 330 of about 355,535 (359)

Targeting Apoptosis Pathways in Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2005
exaly  

[Side effects of anti-arrhythmia agents aprindine and prajmalium bitartrate, in children].

, 1982
H Kamanaoroo, A. Lunkenheimer, Heike Löser, F Hilgenberg, Denise Palm   +4 more
openalex  

[Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation].

, 2003
Н. В. Каверина, V. V. Lyskovtsev, Ekaterine Popova   +2 more
openalex  

[Anti-arrhythmogenic effect of anti-arrhythmia agents].

, 1976
Kovács István, Róbert Károly
openalex  

[Arrhythmogenic effects of anti-arrhythmia agents].

Therapie, 1986
F, Fillette, B, Dupuis, Y, Grosgogeat
openaire   +2 more sources

[Hemodynamic effects of a new anti-arrhythmia agent: mexiletine].

, 1980
Tomassetti, F Fontana, M Masi, Andrea Mezzetti, G Poggiopollini, A Cuppini, Franco Cuccurullo   +6 more
openalex  

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Ca-A Cancer Journal for Clinicians, 2013
exaly  

[Effective electric cardioversion with low-energy stimuli in a patient with paroxysmal tachycardia treated previously with digitalis and anti-arrhythmia agents].

, 1978
Józef Drzewoski, Krzysztof Chojnowski, M Batorowicz   +2 more
openalex  

[Stepwise plan for anti-arrhythmia therapy. Sotalol: the class III anti-arrhythmia agent in the foreground. Report from the news conference: Anti-Arrhythmia Therapy. Frankfurt, 13 October 1993].

, 1994

openalex  

[Classification and application of anti-arrhythmia agents].

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1984
L, Seipel, G, Breithardt
openaire   +1 more source